Status and phase
Conditions
Treatments
About
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with relapsed/refractory, locally advanced inoperable, or metastatic solid tumors
Full description
The main objectives of the study are to establish the safety, recommended Phase 2 dose (RP2D), pharmacokinetics (pk), and preliminary anti-tumour activity of 177Lu-BetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with solid tumors who may benefit from this treatment and who meet the study eligibility criteria.
The study is divided into 2 phases. Phase 1 is the dose escalation phase to establish the safety profile of 177Lu-BetaBart and to determine the maximum tolerated dose (MTD) and/or RP2D of 177Lu-BetaBart.
Phase 2a is the dose expansion phase to evaluate preliminary anti-tumor activity and to confirm the safety of 177Lu-BetaBart in select patient populations.
Each phase consists of a Screening Period, a Treatment Period, and a Safety and Long-term Follow-up Period. The estimated total time on study is 22 weeks excluding the Long-term Follow-up Period.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Participants ≥ 18 years of age.
Participants with a documented history of histopathologically confirmed CRPC*, CRC, NSCLC, SCLC, HNSCC, ovarian cancer, cervical cancer, endometrial cancer, TNBC, or ESCC.
a. *Progressive CRPC defined by at least one of the following criteria: i. Two consecutive increases in PSA measured at least 1 week apart. ii. Soft tissue progression defined as a ≥20% increase in the sum of the diameter or the appearance of one or more new lesions by computed tomography (CT)/magnetic resonance imaging (MRI).
iii. Progression of bone disease defined by Prostate Cancer Working Group 3 (PCWG3) as evaluable disease or new bone lesions by bone scan.
iv. Identification of new soft tissue or bone lesions on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.
b. *Metastatic disease defined as either or both of the following: i. Documented M1 disease on conventional imaging ii. Identification of bone lesion(s), extra-pelvic soft tissue lesion(s), or visceral metastases on PSMA PET imaging with an FDA-approved imaging agent c. *Progression following treatment with ADT and at least one ARSI . e. Participants with liver metastases if they meet the following criteria: i. ≤3 lesions ii. All lesions must be ≤2 cm in the short axis iii. SUVmean ≥2 x that of liver parenchyma g. Participants with TNBC if pathology results confirm the following: i. Estrogen receptor expression <1%, ii. Progesterone receptor expression <1%, iii. Human epidermal growth factor receptor 2 (HER2) negative, defined as IHC 0 or 1+, or IHC 2+ with negative in situ hybridization (ISH)
Participants must have documented disease progression during or after their most recent line of anticancer therapy. Participants must be refractory to or intolerant of standard of care therapy or have no standard of care therapy available that is likely to provide clinical benefit.
Must have at least 1 measurable target lesion according to RECIST v1.1.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Participants must have a life expectancy of ≥ 4 months in the opinion of the Investigator.
Participants of child-bearing potential (CBP) must have a negative β-hCG test and must not be breastfeeding.
Participants of CBP must agree to use a highly effective method of contraception.
Participants with previously treated brain metastases are eligible to participate if:
Exclusion Criteria:
History of prior organ transplant.
Any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer.
Have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Residual toxicity ≥ Grade 2 from prior anti-cancer therapy
History of uncontrolled allergic reactions and/or known or expected hypersensitivity to protein therapeutics.
Inadequate organ functions as reflected in laboratory parameters:
Participants requiring blood product transfusion within 2 weeks of first dose of 177Lu-BetaBart.
*Participants with CRPC who have received prior Lu-177-PSMA radioligand therapy.
Clinically significant cardiovascular disease
Participation in any other interventional investigational trial
Participants who are pregnant or breastfeeding.
Major surgery within 4 weeks prior to first dose of 177Lu-BetaBart.
Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, ≤ 28 days prior to the first dose of 177Lu-BetaBart.
Known active hepatitis B or known active hepatitis C infection.
Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s)
Untreated moderate to severe hydronephrosis
For CRPC participants, prescence of a superscan by nuclear medicine/99mTc bone scan.
Active autoimmune disease that has required systemic treatment within 90 days.
Any other clinically significant comorbidities, which in the judgment of the investigator could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the subject to safety risks.
Primary purpose
Allocation
Interventional model
Masking
61 participants in 1 patient group
Loading...
Central trial contact
Dimitris Voliotis, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal